Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + Lenvatinib in Neoadjuvant HNSCC
NCT07550972Phase 2Enrolling by invitation
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, lenvatinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Zhejiang Provincial People's Hospital. Started May 2026; status: enrolling by invitation.
02
Drugs
pertuzumablenvatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07550972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07550972.